source
- Alnylam lowers Amvuttra sales outlook amid waning demand, shares slideAlnylam released its second‑quarter earnings, highlighting a challenging year for the biotech firm. The report showed continued pressure on its product portfolio. The company cut its full‑year sal…
- Rising oil prices could lift manufacturing costs of an HIV drug, Unitaid report saysRising oil prices, driven in part by geopolitical tensions, have raised concerns about the stability of medicine supply chains. Analysts note that higher energy costs can translate into increased p…